Basic Toradol Information

• INN (International Nonproprietary Name): Ketorolac Tromethamine
• Brand Names Available In Australia: Toradol, Ketorolac
• ATC Code: M01AB15
• Forms & Dosages: Tablets 10 mg; Injection 10 mg/mL and 30 mg/mL ampoules/vials; Eye drops 0.5% (Acular).
• Manufacturers In Australia: Hoffmann-La Roche (Toradol) and multiple generic suppliers such as Sandoz, Teva, Mylan and Normon are listed internationally.
• Registration Status In Australia: Widely registered and supplied as a prescription-only medicine.
• OTC / Rx Classification: Prescription-only (Rx).

Latest Research Highlights

Clinicians ask: How effective is ketorolac and what are the real safety limits?

Recent Australian audits and international trials from 2021–2025 confirm ketorolac's potency for short-term moderate to severe pain.

Randomised controlled trials and meta-analyses show parenteral ketorolac provides rapid analgesia comparable to short opioid courses for postoperative pain.

Those studies report less sedation with ketorolac compared with opioids but note higher rates of gastrointestinal and renal adverse events when use extends beyond recommended duration.

Australian emergency department and perioperative audits report meaningful opioid-sparing when ketorolac is used as a single dose or short course.

TGA adverse-event reports list renal impairment and gastrointestinal bleeding among the leading harms associated with ketorolac in Australia.

Historical regulatory action in Germany, where ketorolac was withdrawn in 1993, underlines ongoing safety vigilance.

Practical takeaway: Ketorolac is effective but strictly time-limited to five days or less and contraindicated in renal disease.

Clinical Effectiveness In Australia

Patients often want to know how ketorolac is used locally.

Australian hospitals commonly use ketorolac, marketed as Toradol, as a short-term analgesic in emergency departments and perioperative care.

Parenteral formulations are favoured in hospital formularies for rapid onset, while oral tablets are used for brief outpatient courses.

PBS coverage is variable and many inpatient uses are supplied under hospital provisioning rather than general PBS prescriptions.

TGA-monitored safety data for Australia align with international findings: effective analgesia with a narrow therapeutic window due to COX‑1 and COX‑2 inhibition and prostaglandin suppression.

Real-world audits in Australia note opioid-sparing benefits but emphasise the need for monitoring renal function and gastrointestinal symptoms.

• Data Highlight: Documented opioid reduction in audited perioperative pathways; specific percentages vary by audit and hospital protocol.
• Data Highlight: TGA reports identify renal impairment and GI bleeding as common serious adverse events.

Clinicians balance fast analgesic effect against TGA safety guidance and local hospital protocols.

Pharmacists act as gatekeepers for community dispensing, checking renal history and co‑medication before supply.

Indications And Expanded Uses

People ask: What is ketorolac officially approved for and what do clinicians sometimes use it for off-label?

TGA-approved uses focus on short-term management of moderate to severe pain, particularly postoperative and acute musculoskeletal pain.

Common parenteral use in Australia is for acute pain control in hospital settings.

Off-label practices include single-dose IM/IV ketorolac for severe migraine attacks presenting to the emergency department.

Ophthalmic ketorolac, as separate formulations such as Acular, is used for postoperative ocular inflammation and is a distinct product line.

• Approved Indications: Short-term moderate to severe pain, postoperative pain management.
• Common Off‑Label Uses: Single-dose IV/IM for acute severe migraine in ED; specialist short courses where benefits outweigh risks.
• Ophthalmic Formulations: Ketorolac 0.5% eye drops for postoperative inflammation (Acular).

Off-label use must respect the ≤5‑day maximum for systemic ketorolac and be guided by local protocols and documented consent.

Composition And Brand Landscape

What exactly is in Toradol and which brands are available?

The active ingredient is ketorolac tromethamine, a non‑selective cyclooxygenase inhibitor with strong analgesic potency.

In Australia, Toradol and generic ketorolac are supplied in 10 mg oral tablets and injectables as 10 mg/mL and 30 mg/mL ampoules or vials.

International manufacturers listed include Hoffmann‑La Roche (Toradol) plus generic manufacturers such as Sandoz, Teva, Pfizer, Mylan and Normon.

Choice of brand in Australia is often driven by hospital contracts and community supplier stock.

Product labelling notes the tromethamine salt and provides dosing and storage instructions.

Contraindications And Special Precautions

Patients commonly worry about who must avoid ketorolac.

Absolute contraindications include known hypersensitivity to NSAIDs or ketorolac.

Other absolute contraindications are active or recent gastrointestinal bleeding, peptic ulcer disease, severe renal impairment and haemorrhagic diathesis.

Ketorolac must not be used in labour or late pregnancy and is contraindicated in established NSAID‑sensitive asthma.

Relative risk groups requiring close monitoring include elderly patients, those on anticoagulants or antiplatelets, people with cardiovascular disease, and those with mild to moderate hepatic impairment.

Indigenous Australians often have higher baseline renal disease prevalence and need culturally safe shared decision‑making and closer monitoring.

Daily‑life restrictions include avoiding heavy machinery or driving if drowsy or dizzy and limiting alcohol because of increased GI bleed risk.

• Checklist For Prescribers: Baseline creatinine, bleed risk assessment, pregnancy test where relevant.
• Absolute Contraindications: Hypersensitivity, active GI bleed, severe renal impairment, haemorrhagic diathesis, labour/late pregnancy, NSAID‑sensitive asthma.
• Relative Contraindications: Elderly, anticoagulant use, cardiovascular disease, hepatic impairment.

Dosage Guidelines

One common question is what dose to use and for how long.

Standard adult oral dosing is 10 mg every 4–6 hours as needed, with careful total‑duration limits.

Parenteral dosing is typically 10–30 mg IV or IM every 6 hours, again with strict cumulative dose and duration controls.

The maximum recommended duration for systemic oral or parenteral ketorolac is five days or less.

Paediatric dosing is rare and specialist‑guided, for example 0.5–1 mg/kg IV/IM where used.

Elderly patients should receive lower doses, for example 10 mg dosing and a reduced maximum daily dose due to increased adverse event risk.

Renal impairment is generally a contraindication and requires avoidance or significant dose reduction.

Highlighted Dose Adjustment: Reduce dose in the elderly and avoid in moderate‑to‑severe renal impairment.

Counselling Point: Do not exceed the recommended duration and record baseline renal function where possible.

Interactions Overview

Most people want to know which medicines increase risk when taken with ketorolac.

Ketorolac increases bleeding risk with anticoagulants and antiplatelet drugs such as warfarin and DOACs.

Concomitant use with ACE inhibitors, ARBs and diuretics can add nephrotoxic risk and reduce renal perfusion.

SSRIs increase the risk of gastrointestinal bleeding when combined with ketorolac.

Corticosteroids may increase risk of GI adverse events when taken with NSAIDs.

Alcohol increases gastrointestinal bleeding risk.

Pharmacists should check a patient’s My Health Record or current medication list before supply and counsel on interaction risks.

Cultural Perceptions And Patient Habits

Patients often ask if ketorolac is safe and affordable.

Australian patients are commonly cautious about potent analgesics and often seek pharmacist advice before accepting a short‑term NSAID prescription.

Price sensitivity and PBS reliance influence choices, with many preferring PBS-subsidised or generic options when available.

Rural patients may rely on telehealth e‑prescriptions and local community pharmacists because 24/7 hospital access is limited.

Stockouts of injectable ketorolac can be an access issue outside major hospital centres.

Indigenous communities may have higher baseline renal disease and may distrust medications introduced without culturally safe explanation.

• Tip For Clinicians: Use shared decision‑making and involve Aboriginal health services when treating Indigenous patients.
• Tip For Rural Care: Confirm local pharmacy stock before arranging a telehealth prescription.

Online forums often praise the opioid‑sparing benefit but express concern about renal and gastrointestinal harms.

Availability And Pricing Patterns

Readers want to know where to get toradol and how much it costs.

Toradol and generic ketorolac are prescription‑only in Australia and are distributed through hospital formularies and community pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart.

PBS listing varies by indication, and many acute inpatient uses are supplied under hospital provision rather than general PBS prescriptions.

Outpatient prescriptions may attract private cost and patients are advised to check local pharmacy pricing and PBS schedules.

Injectables are more commonly supplied by hospitals than community pharmacies and community stock can vary.

Steps To Obtain Via Telehealth Or Rural Pharmacy: Confirm prescription, check stock with chosen pharmacy, plan safe transport for injectables where required.

Pharmacists should confirm supply, advise on storage and request renal history before dispensing.

In our online pharmacy, toradol is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences

People often ask what they can use instead of ketorolac.

Alternatives include over‑the‑counter NSAIDs such as ibuprofen and naproxen for mild to moderate pain and paracetamol as first‑line analgesia.

Diclofenac remains an alternative in topical or oral forms, while opioids are reserved for appropriately selected severe pain despite dependency and sedation risks.

For migraine specifically, triptans such as sumatriptan are migraine‑specific and are preferred where suitable.

Decision factors should include comorbidities, bleeding risk, renal function, access and PBS subsidisation.

FAQ

Q1: Can I get Toradol without a prescription?

No. Ketorolac is prescription-only in Australia except where supplied by hospitals.

Q2: Is it safe in pregnancy or breastfeeding?

Ketorolac is contraindicated in late pregnancy and is generally avoided in breastfeeding without specialist advice due to neonatal and maternal bleeding risks.

Q3: Can I take Toradol with paracetamol or an opioid?

Short-term combination with paracetamol is commonly used for multimodal analgesia; combination with opioids may be used in hospital but requires monitoring for additive adverse effects.

Q4: What if I have kidney disease?

Ketorolac is generally avoided in renal impairment and alternatives should be discussed with a prescriber.

• When To Seek Urgent Care: Black or tarry stools, vomiting blood, sudden shortness of breath, reduced urine output or signs of anaphylaxis.

Contact your GP, pharmacist or the emergency department for severe symptoms.

Guidelines For Proper Use

What should a pharmacist do when dispensing ketorolac?

Confirm the indication and that intended duration will not exceed five days.

Check baseline renal function and bleeding history where possible.

Review My Health Record or the patient’s medication list for anticoagulants, SSRIs, ACE inhibitors or diuretics.

Advise patients on common side effects such as nausea, dizziness and GI upset and on serious signs requiring urgent care.

Instruct patients to stop and seek urgent care for black/tarry stools, haematuria or reduced urine output.

Document counselling and storage instructions.

• Storage: Room temperature 15–25°C; protect tablets and injections from moisture; do not freeze injectables.
• Counselling Script Template: “This is ketorolac (Toradol). Take only as directed for up to five days. Avoid NSAIDs if you have kidney disease or are taking blood thinners. Seek urgent care for any signs of bleeding or reduced urine output.”

For rural or telehealth patients, provide clear written instructions and confirm local pharmacy stock and follow‑up plans.

Delivery Across Australia